Form 4 for IMNM Immunome Inc.
Accepted 2023-10-03 00:00:00 ET · period of report 2023-10-02 · accession 0001104659-23-106486 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-03 | 2023-10-02 | IMNM | RAPP MICHAEL | Dir | A - Grant | $5.91 | +253.8K | 1.07M | +31% | +$1.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-02 | A | A | 253,806 | $5.91 | 1,071,172 | D | — | — | (F1) The shares were issued to the Reporting Person pursuant to the closing of the transactions contemplated by that certain Subscription Agreement, dated as of June 29, 2023, by and among the Reporting Person and the Issuer and in connection with the closing of to the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023, by and among the Issuer, Morphimmune Inc., a Delaware corporation, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer. |